multiple sclerosis

Novartis confident in Gilenya despite FDA call out
Novartis confident in Gilenya despite FDA call out
Biopharma Dive
Novartis
Gilenya
MS
multiple sclerosis
Flag link:
Mylan's generic Copaxone wins in court, but market barriers remain
Mylan's generic Copaxone wins in court, but market barriers remain
Biopharma Dive
Teva Pharmaceutical
Copaxone
patents
MS
multiple sclerosis
Flag link:
Merck KGaA posts mixed data from their big PhIIb MS study on evobrutinib — spurring plenty of questions
Merck KGaA posts mixed data from their big PhIIb MS study on evobrutinib — spurring plenty of questions
Endpoints
Merck KGaA
evobrutinib
MS
multiple sclerosis
Flag link:
Can Sanofi's new long-term Lemtrada data amp up sales in a crowded MS field?
Can Sanofi's new long-term Lemtrada data amp up sales in a crowded MS field?
Fierce Pharma
Sanofi
Lemtrada
MS
multiple sclerosis
Flag link:
Roche and Novartis Strengthen Their Presence in the MS Market
Roche and Novartis Strengthen Their Presence in the MS Market
BioSpace
Genentech
Roche
Ocrevus
Novartis
siponimod
FDA
MS
multiple sclerosis
Flag link:
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
CP Wire
Celgene
ozanimod
multiple sclerosis
Flag link:
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
Celgene
ozanimod
multiple sclerosis
Flag link:
Novartis bets PRV on its next big multiple sclerosis drug — eyes US, EU approvals in ’19
Novartis bets PRV on its next big multiple sclerosis drug — eyes US, EU approvals in ’19
Endpoints
Novartis
siponimod
MS
multiple sclerosis
Europe
Flag link:
Servier drops GeNeuro’s multiple sclerosis drug after midphase miss
Servier drops GeNeuro’s multiple sclerosis drug after midphase miss
Fierce Biotech
Servier
GeNeuro
MS
multiple sclerosis
GNbAC1
Flag link:
Federal court rules Ampyra patents invalid, Acorda stock sinks 25%
Federal court rules Ampyra patents invalid, Acorda stock sinks 25%
Biopharma Dive
Acorda Therapeutics
MS
multiple sclerosis
AMPYRA
patents
Flag link:
MS Society protests NICE rejection of Ocrevus for primary progressive MS
MS Society protests NICE rejection of Ocrevus for primary progressive MS
BioCentury
NICE
UK
MS
multiple sclerosis
Ocrevus
ocrelizumab
Roche
Flag link:
Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst
Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst
Fierce Pharma
Biogen
Teva Pharmaceutical
MS
multiple sclerosis
payers
Flag link:
Analyst sees positive future for Merck KGaA in MS market, as FDA accepts Mavenclad for review
Analyst sees positive future for Merck KGaA in MS market, as FDA accepts Mavenclad for review
The Pharma Letter
Merck KGaA
Mavenclad
cladribine
MS
multiple sclerosis
Flag link:
Novartis' MS patent win also a win for Celgene's impending MS drug: analyst
Novartis' MS patent win also a win for Celgene's impending MS drug: analyst
Medical Marketing and Media
Celgene
Novartis
ozanimod
Gilenya
MS
multiple sclerosis
patents
Flag link:
Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study
Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study
Fierce Pharma
Roche
MS
multiple sclerosis
Ocrevus
FDA
vaccines
Flag link:
Celgene's timeline for refiling ozanimod gets mixed reviews
Celgene's timeline for refiling ozanimod gets mixed reviews
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
FDA
Flag link:
A metabolite will make or break Celgene's ozanimod
A metabolite will make or break Celgene's ozanimod
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
metabolite
Flag link:
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
Celgene Corporation
multiple sclerosis
ozanimod
Flag link:
Lemtrada Treatment Effects in MS Patients Maintained Over Seven Years
Lemtrada
Sanofi
Relapsing Remitting Multiple Sclerosis
multiple sclerosis
Flag link:
Roche Acquires MS Remyelination Program from Versant Ventures
Roche Acquires MS Remyelination Program from Versant Ventures
CP Wire
Roche
MS
multiple sclerosis
remylination
M&A
Versant Ventures
Inception 5
Flag link:

Pages